Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Aditi Singhai
Alison Sathe
Anders Vinther
Anne-Caroline Boillot
Barbara W. Unger
Barry Price
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Khushboo Agrawal
Mark Agostino
Michael de la Torre
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Tashil Sharma
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

FSMA in a Nutshell

No items found.

20,000 FDA Warning Letters

No items found.

The End of Homeopathic Products’ Free Pass

No items found.

Generic Drugs | A Guidance on FDA Guidance

No items found.

Deep Pockets | Does the FDA Get Tougher if the Owner Gets Richer?

No items found.

New CDRH Guidance in October

No items found.

Recent Generic Drug Guidance

No items found.

Introducing FDAzilla’s New CEO

No items found.

PRESS RELEASE – FDAzilla Announces New CEO

No items found.

The Heightened Importance of Contract Manufacturing Organizations

No items found.
Enforcement

FDA Sent These 11 Warning Letters for Pharma Companies | August 2017

No items found.

Summer Enforcement Actions for Compounding Pharmacies and Outsourcing Facilities

No items found.

US-EU Mutual Recognition Agreement of 2017

No items found.
Enforcement

FDA Sent These 6 Warning Letters for Pharma Companies | May 2017

No items found.

28 Unique Data Integrity Deficiencies That Aren’t Really Unique

No items found.

When Will the FDA Move On from Data Integrity?

No items found.

Warning Letters 2016 – Data Governance & Data Integrity

No items found.

Why is No One Talking About This? 2016 was the Year the FDA Exploded on China

No items found.